고형 종양 검사 시장 : 종류별, 용도별, 최종사용자별 - 세계 기회 분석과 산업 예측(2021-2031년)

The global solid tumor testing market was valued at $ 23,751.4 million in 2021 and is projected to reach $ 46,722.2 million by 2031, registering a CAGR of 7.0% from 2022 to 2031. Solid tumor testing is a procedure used to evaluate the primary tumors and determine the extent/location of any metastases. The tumor testing in turn allows effective treatment options to be considered so that the spread of cancerous cells can be avoided. A tumor is an abnormal clump of cells. When someone has a solid tumor, that means the tumor doesn't contain any liquid or cysts. Solid tumor testing is a valuable technique that is used for the identification and visualization of solid tumors in clinical diagnostics.

In addition, Solid tumors can be tested through genetic testing and conventional testing. In genetic testing, there are various techniques such as next-generation sequencing (NGS), real-time PCR (RT-PCR), fluorescent In-Situ hybridization (FISH), and fragment analysis that are used for the diagnosis of tumors at early stages. In conventional testing, urine and blood tests, computerized tomography (CT) scan, bone scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, ultrasound and X-ray, and biopsy are used for the diagnosis of solid tumors.

The key factors that drive the growth of the market are an increase in the prevalence of the geriatric population that is prone to solid tumors, a rise in the prevalence of solid tumors in the world, and a rise in healthcare expenditure boosts the market growth.

For instance, according to American Cancer Society January 2021, estimated new cancer cases of Female breast (281,550), Uterine cervix (14,480), Colon & rectum (149,500), Uterine corpus (66,570), Lung & bronchus (235,760), Melanoma of the skin (106,110), non-Hodgkin lymphoma (81,560), Prostate (248,530), Urinary bladder (83,730) were diagnosed in 2021 in the U.S. Each year, approximately 4,00,000 children develop cancer. Overall cancer incidence rates, or rates of new cancers, continue to rise slightly in women and children

However, the dearth of skilled professionals restricts the market growth in the forecast period. Moreover, the rise in technological advancements in solid tumor testing, the increase in several type approvals, and the availability of reimbursements for solid tumor testing tests offer lucrative opportunities to the market players operating in the solid tumor testing market.

The global Solid tumor testing market is segmented into type, application, end-user, and region. By type, the market is categorized into genetic testing and conventional testing. The genetic testing segment is further classified into next-generation sequencing (NGS), real-time PCR (RT-PCR), fluorescent In-Situ hybridization (FISH), and fragment analysis. By application, the market is segmented into prostate, breast, colorectal, endometrial, lung, melanoma, brain, thyroid, liver, ovarian, and others (vaginal & vulvar, bladder, cervical, head & neck, and mesothelioma). By end user, the market is categorized into hospitals, pharmaceutical, and biotechnology companies, contract research organizations, and academic research institutions. By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global Solid tumor testing market are Abbott Laboratories, Agilent Technologies, Biocare Medical, LLC., F. Hoffmann-La Roche Ltd, Illumina, Inc., MedGenome, Myriad Genetics, QIAGEN N.V., Quest Diagnostics, and Thermo Fischer Scientific, Inc

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the solid tumor testing market analysis from 2021 to 2031 to identify the prevailing solid tumor testing market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the solid tumor testing market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes an analysis of the regional as well as global solid tumor testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

• Genetic Testing
  • Genetic Test Type
  • Next generation sequencing (NGS)
  • Real-time PCR (RT-PCR)
  • Fluorescent In-Situ Hybridization (FISH)
  • Fragment Analysis
• Conventional Testing

By Application

• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Brain
• Thyroid
• Liver
• Ovarian
• Others

By End User

• Hospitals
• Pharmaceutical and biotechnology companies
• Contract research organizations
• Academic research institutions

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • QIAGEN
  • QUEST DIAGNOSTICS INCORPORATED
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Biocare Medical LLC
  • , F. Hoffmann-La Roche AG
  • ILLUMINA, INC.
  • MedGenome Labs Private Ltd
  • MYRIAD GENETICS, INC.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: SOLID TUMOR TESTING MARKET, BY TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Genetic Testing
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
  • 4.2.4 Genetic Testing Solid Tumor Testing Market by Genetic Test Type
    • 4.2.4.1 Next generation sequencing (NGS) Market size and forecast, by region
    • 4.2.4.2 Real-time PCR (RT-PCR) Market size and forecast, by region
    • 4.2.4.3 Fluorescent In-Situ Hybridization (FISH) Market size and forecast, by region
    • 4.2.4.4 Fragment Analysis Market size and forecast, by region
• 4.3 Conventional Testing
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country

CHAPTER 5: SOLID TUMOR TESTING MARKET, BY APPLICATION

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Prostate
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Breast
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Colorectal
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country
• 5.5 Endometrial
  • 5.5.1 Key market trends, growth factors and opportunities
  • 5.5.2 Market size and forecast, by region
  • 5.5.3 Market analysis by country
• 5.6 Lung
  • 5.6.1 Key market trends, growth factors and opportunities
  • 5.6.2 Market size and forecast, by region
  • 5.6.3 Market analysis by country
• 5.7 Melanoma
  • 5.7.1 Key market trends, growth factors and opportunities
  • 5.7.2 Market size and forecast, by region
  • 5.7.3 Market analysis by country
• 5.8 Brain
  • 5.8.1 Key market trends, growth factors and opportunities
  • 5.8.2 Market size and forecast, by region
  • 5.8.3 Market analysis by country
• 5.9 Thyroid
  • 5.9.1 Key market trends, growth factors and opportunities
  • 5.9.2 Market size and forecast, by region
  • 5.9.3 Market analysis by country
• 6.0 Liver
  • 6.0.1 Key market trends, growth factors and opportunities
  • 6.0.2 Market size and forecast, by region
  • 6.0.3 Market analysis by country
• 6.1 Ovarian
  • 6.1.1 Key market trends, growth factors and opportunities
  • 6.1.2 Market size and forecast, by region
  • 6.1.3 Market analysis by country
• 6.2 Others
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country

CHAPTER 6: SOLID TUMOR TESTING MARKET, BY END USER

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospitals
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Pharmaceutical and biotechnology companies
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
• 6.4 Contract research organizations
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country
• 6.5 Academic research institutions
  • 6.5.1 Key market trends, growth factors and opportunities
  • 6.5.2 Market size and forecast, by region
  • 6.5.3 Market analysis by country

CHAPTER 7: SOLID TUMOR TESTING MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Type
    • 7.2.2.1 North America Genetic Testing Solid Tumor Testing Market by Genetic Test Type
  • 7.2.3 North America Market size and forecast, by Application
  • 7.2.4 North America Market size and forecast, by End User
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Type
    • 7.2.5.1.2 Market size and forecast, by Application
    • 7.2.5.1.3 Market size and forecast, by End User
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Type
    • 7.2.5.2.2 Market size and forecast, by Application
    • 7.2.5.2.3 Market size and forecast, by End User
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Type
    • 7.2.5.3.2 Market size and forecast, by Application
    • 7.2.5.3.3 Market size and forecast, by End User
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Type
    • 7.3.2.1 Europe Genetic Testing Solid Tumor Testing Market by Genetic Test Type
  • 7.3.3 Europe Market size and forecast, by Application
  • 7.3.4 Europe Market size and forecast, by End User
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Type
    • 7.3.5.1.2 Market size and forecast, by Application
    • 7.3.5.1.3 Market size and forecast, by End User
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Type
    • 7.3.5.2.2 Market size and forecast, by Application
    • 7.3.5.2.3 Market size and forecast, by End User
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Type
    • 7.3.5.3.2 Market size and forecast, by Application
    • 7.3.5.3.3 Market size and forecast, by End User
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Type
    • 7.3.5.4.2 Market size and forecast, by Application
    • 7.3.5.4.3 Market size and forecast, by End User
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Type
    • 7.3.5.5.2 Market size and forecast, by Application
    • 7.3.5.5.3 Market size and forecast, by End User
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Type
    • 7.3.5.6.2 Market size and forecast, by Application
    • 7.3.5.6.3 Market size and forecast, by End User
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Type
    • 7.4.2.1 Asia-Pacific Genetic Testing Solid Tumor Testing Market by Genetic Test Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Application
  • 7.4.4 Asia-Pacific Market size and forecast, by End User
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Type
    • 7.4.5.1.2 Market size and forecast, by Application
    • 7.4.5.1.3 Market size and forecast, by End User
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Type
    • 7.4.5.2.2 Market size and forecast, by Application
    • 7.4.5.2.3 Market size and forecast, by End User
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Market size and forecast, by Type
    • 7.4.5.3.2 Market size and forecast, by Application
    • 7.4.5.3.3 Market size and forecast, by End User
    • 7.4.5.4 India
    • 7.4.5.4.1 Market size and forecast, by Type
    • 7.4.5.4.2 Market size and forecast, by Application
    • 7.4.5.4.3 Market size and forecast, by End User
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Type
    • 7.4.5.5.2 Market size and forecast, by Application
    • 7.4.5.5.3 Market size and forecast, by End User
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Type
    • 7.4.5.6.2 Market size and forecast, by Application
    • 7.4.5.6.3 Market size and forecast, by End User
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Type
    • 7.5.2.1 LAMEA Genetic Testing Solid Tumor Testing Market by Genetic Test Type
  • 7.5.3 LAMEA Market size and forecast, by Application
  • 7.5.4 LAMEA Market size and forecast, by End User
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Type
    • 7.5.5.1.2 Market size and forecast, by Application
    • 7.5.5.1.3 Market size and forecast, by End User
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Type
    • 7.5.5.2.2 Market size and forecast, by Application
    • 7.5.5.2.3 Market size and forecast, by End User
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Type
    • 7.5.5.3.2 Market size and forecast, by Application
    • 7.5.5.3.3 Market size and forecast, by End User
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Type
    • 7.5.5.4.2 Market size and forecast, by Application
    • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 QIAGEN
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 QUEST DIAGNOSTICS INCORPORATED
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Abbott Laboratories
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Agilent Technologies Inc.
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Biocare Medical LLC
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 , F. Hoffmann-La Roche AG
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 ILLUMINA, INC.
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 MedGenome Labs Private Ltd
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 MYRIAD GENETICS, INC.
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Thermo Fisher Scientific, Inc.
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments